306 related articles for article (PubMed ID: 25902832)
1. Molecular characterization and targeted therapeutic approaches in breast cancer.
Toss A; Cristofanilli M
Breast Cancer Res; 2015 Apr; 17(1):60. PubMed ID: 25902832
[TBL] [Abstract][Full Text] [Related]
2. Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.
Chen L; Jenjaroenpun P; Pillai AM; Ivshina AV; Ow GS; Efthimios M; Zhiqun T; Tan TZ; Lee SC; Rogers K; Ward JM; Mori S; Adams DJ; Jenkins NA; Copeland NG; Ban KH; Kuznetsov VA; Thiery JP
Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2215-E2224. PubMed ID: 28251929
[TBL] [Abstract][Full Text] [Related]
3. Radiation-Induced Gene Expression Changes in High and Low Grade Breast Cancer Cell Types.
Bravatà V; Cava C; Minafra L; Cammarata FP; Russo G; Gilardi MC; Castiglioni I; Forte GI
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29617354
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1, breast cancer and ionizing radiation.
Pucci M; Bravatà V; Forte GI; Cammarata FP; Messa C; Gilardi MC; Minafra L
Cancer Genomics Proteomics; 2015; 12(3):143-52. PubMed ID: 25977173
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2‑positive breast cancer.
Zubor P; Hatok J; Moricova P; Kapustova I; Kajo K; Mendelova A; Sivonova MK; Danko J
Mol Med Rep; 2015 Feb; 11(2):1421-7. PubMed ID: 25373323
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.
Fadoukhair Z; Zardavas D; Chad MA; Goulioti T; Aftimos P; Piccart M
Oncogene; 2016 Apr; 35(14):1743-9. PubMed ID: 26119941
[TBL] [Abstract][Full Text] [Related]
8. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
11. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
12. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer intratumour heterogeneity: current status and clinical implications.
Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of breast cancer cell lines through multiple omic approaches.
Smith SE; Mellor P; Ward AK; Kendall S; McDonald M; Vizeacoumar FS; Vizeacoumar FJ; Napper S; Anderson DH
Breast Cancer Res; 2017 Jun; 19(1):65. PubMed ID: 28583138
[TBL] [Abstract][Full Text] [Related]
15. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
16. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
17. High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression.
Sgarra R; Pegoraro S; Ros G; Penzo C; Chiefari E; Foti D; Brunetti A; Manfioletti G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):216-229. PubMed ID: 29518471
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
19. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
Santa-Maria CA; Gradishar WJ
JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
[TBL] [Abstract][Full Text] [Related]
20. Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?
Peintinger F
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):21-6. PubMed ID: 24346126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
